Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Diagnostic Criteria, Classification Lacking for Vasculitis; New Research in Treatment for Systemic Sclerosis

Thomas R. Collins  |  Issue: September 2016  |  September 12, 2016

LONDON—Despite the detailed terminology for describing vasculitis established by the Chapel Hill Consensus (CHC) in 2012, the field badly needs better classification and diagnostic criteria for the group of diseases, an expert said in a presentation at the Annual Congress of the European League Against Rheumatism (EULAR 2016).

It’s a topic that is now being rigorously studied, with results likely coming in the next year or two, said Cees Kallenberg, MD, PhD, the former head of the department of rheumatology and immunology at the University Medical Center Groningen in The Netherlands, in a talk on the latest in the field.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Vocabulary of Vasculitis

The umbrella term vasculitis—inflammation of the blood vessels that can affect a wide variety of organs—covers a broad range of diseases and syndromes based on vessel size, organ involvement and the likely causes. The groupings in the nomenclature from the CHC include large-, medium- and small-vessel vasculitis; single-organ vasculitis, such as cutaneous arteritis; primary central nervous system vasculitis; and those associated with probable etiologies, such as vasculitis associated with hepatitis B and drug-associated immune-complex vasculitis.

The problem with this vocabulary is that it “does not give diagnostic or even classification criteria,” Dr. Kallenberg said.

Severe inflammation of the artery (arteritis) (right) in the myocardium. For comparison, a normal healthy artery is shown on the left.

Severe inflammation of the artery (arteritis) (right) in the myocardium. For comparison, a normal healthy artery is shown on the left.

He gave an example from the 1990 American College of Rheumatology classification criteria to convey the need for improvements. The criteria for granulomatosis with polyangiitis (GPA) are nasal or oral inflammation; abnormal chest X-ray; microhematuria; and granulomatous inflammation on biopsy. If someone already has a diagnosis of vasculitis on histology and two of those four are present, a disease can be classified as GPA. But these criteria cannot be used as a diagnostic guide, Dr. Kallenberg said.

“If we use [these] criteria as diagnostic criteria, you must [diagnose] every patient with purulent nasal discharge and microhematuria [with] GPA, which is certainly not right,” he said. “So we definitely need better diagnostic and classification criteria.”

A large, multi-center, international prospective study—the DCVAS study—is underway to design and validate classification and diagnostic criteria, he noted.

ANCA+/-

Another big issue facing the field is whether ANCA-associated and ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) should be considered as two different diseases, given that so many differences exist between the two. For example, the ANCA-associated form is typically a small-vessel vasculitis, while ANCA-negative is marked by tissue infiltration with eosinophils.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsResearch RheumVasculitis Tagged with:ClassificationcriteriaDiagnosisEULAREuropean League Against RheumatismResearchrheumatologySystemic sclerosisTreatmentVasculitis

Related Articles
    Figure 2: Renal Biopsy

    The Classification & Diagnosis of Granulomatosis with Polyangiitis

    August 16, 2018

    Based on the classification system developed by the Chapel Hill Consensus Conference, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis is defined as a necrotizing vasculitis involving small vessels that is associated with myeloperoxidase (MPO) ANCA or proteinase 3 (PR3) ANCA and displays minimal immune deposits. The mechanism behind the pathogenesis of ANCA-associated vasculitis is not fully…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    ACR Winter Rheumatology Symposium: Tips for ANCA Testing

    May 1, 2013

    How to select the correct testing method and interpret conflicting results from antineutrophil cytoplasmic antibody tests

    ilusmedical / shutterstock.com

    The State of Clinical Research in Vasculitis: 2021

    January 19, 2021

    It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences